Cargando…

Conservative treatment of endometrial cancer in women of reproductive age (Review)

Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surge...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourou, Maria Zoi, Matsas, Alkis, Vrekoussis, Thomas, Mastorakos, Georgios, Valsamakis, Georgios, Panoskaltsis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265581/
https://www.ncbi.nlm.nih.gov/pubmed/37323245
http://dx.doi.org/10.3892/mco.2023.2651
_version_ 1785058563153985536
author Bourou, Maria Zoi
Matsas, Alkis
Vrekoussis, Thomas
Mastorakos, Georgios
Valsamakis, Georgios
Panoskaltsis, Theodoros
author_facet Bourou, Maria Zoi
Matsas, Alkis
Vrekoussis, Thomas
Mastorakos, Georgios
Valsamakis, Georgios
Panoskaltsis, Theodoros
author_sort Bourou, Maria Zoi
collection PubMed
description Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy.
format Online
Article
Text
id pubmed-10265581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-102655812023-06-15 Conservative treatment of endometrial cancer in women of reproductive age (Review) Bourou, Maria Zoi Matsas, Alkis Vrekoussis, Thomas Mastorakos, Georgios Valsamakis, Georgios Panoskaltsis, Theodoros Mol Clin Oncol Review Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy. D.A. Spandidos 2023-05-25 /pmc/articles/PMC10265581/ /pubmed/37323245 http://dx.doi.org/10.3892/mco.2023.2651 Text en Copyright: © Bourou et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Bourou, Maria Zoi
Matsas, Alkis
Vrekoussis, Thomas
Mastorakos, Georgios
Valsamakis, Georgios
Panoskaltsis, Theodoros
Conservative treatment of endometrial cancer in women of reproductive age (Review)
title Conservative treatment of endometrial cancer in women of reproductive age (Review)
title_full Conservative treatment of endometrial cancer in women of reproductive age (Review)
title_fullStr Conservative treatment of endometrial cancer in women of reproductive age (Review)
title_full_unstemmed Conservative treatment of endometrial cancer in women of reproductive age (Review)
title_short Conservative treatment of endometrial cancer in women of reproductive age (Review)
title_sort conservative treatment of endometrial cancer in women of reproductive age (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265581/
https://www.ncbi.nlm.nih.gov/pubmed/37323245
http://dx.doi.org/10.3892/mco.2023.2651
work_keys_str_mv AT bouroumariazoi conservativetreatmentofendometrialcancerinwomenofreproductiveagereview
AT matsasalkis conservativetreatmentofendometrialcancerinwomenofreproductiveagereview
AT vrekoussisthomas conservativetreatmentofendometrialcancerinwomenofreproductiveagereview
AT mastorakosgeorgios conservativetreatmentofendometrialcancerinwomenofreproductiveagereview
AT valsamakisgeorgios conservativetreatmentofendometrialcancerinwomenofreproductiveagereview
AT panoskaltsistheodoros conservativetreatmentofendometrialcancerinwomenofreproductiveagereview